TOPICAL TREATMENT WITH BAY b 5097, A NEW BROAD SPECTRUM ANTIMYCOTIC AGENT

Abstract

Summary.— The effect on superficial mycoses of BAY b 5097, a tritylimidazole derivative, applied topically in a 1% solution, was evaluated in a randomized double‐blind study in 54 patients. It was significantly better than a placebo in diseases produced both by Candida albicans and by Trichophyton species. After 3 weeks of treatment, clinical healing was recorded in 57% of the cases and marked improvement in an additional 33%. No side effects were noted.